8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Apr 17, 2026·SEC
Material company update
Apr 1, 2026·SEC
BioXcel Therapeutics, Inc.(BTAI)Earnings, Financials & Key Ratios
BTAI•NASDAQ
Price updated Jun 17, 2026
AboutBioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.Show more
- Revenue$642K-71.7%
- EBITDA-$50M+25.4%
- Net Income-$70M-17.3%
- EPS (Diluted)-5.73+75.6%
- Gross Margin74.45%+1271.7%
- EBITDA Margin-7783.02%-163.5%
- Operating Margin-7829.75%-163.8%
- Net Margin-10887.38%-313.9%
BTAI Key Insights
BioXcel Therapeutics, Inc. (BTAI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BTAI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BTAI Price & Volume
BioXcel Therapeutics, Inc. (BTAI) stock price & volume — 10-year historical chart
Loading chart...
BTAI Growth Metrics
BioXcel Therapeutics, Inc. (BTAI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years19.63%
TTM-63.28%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-88.04%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM50.44%
Return on Capital
10 Years-274.32%
5 Years-383.79%
3 Years-596.21%
Last Year-1416.97%
BTAI Recent Earnings
BioXcel Therapeutics, Inc. (BTAI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.54-1.4%
$0.53
Rev
$206,000-46.0%
$381,491
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.58-70.6%
$0.34
Rev
$256,000+69.0%
$151,520
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$2.18-41.6%
$1.54
Rev
$98,000-42.0%
$169,020
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$2.45-6.5%
$2.30
Rev
$120,000-53.4%
$257,500
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.54vs $0.53-1.4% | $206,000vs $381,491-46.0% |
| Q2 2026 | Mar 26, 2026 | $0.58vs $0.34-70.6% | $256,000vs $151,520+69.0% |
| Q4 2025 | Nov 12, 2025 | $2.18vs $1.54-41.6% | $98,000vs $169,020-42.0% |
| Q3 2025 | Aug 12, 2025 | $2.45vs $2.30-6.5% | $120,000vs $257,500-53.4% |
Based on last 12 quarters of dataView full earnings history →
BTAI Peer Comparison
BioXcel Therapeutics, Inc. (BTAI) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.7B | 21.60 | 9.43 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.67B | 22.64 | 6.86 | 18.52% | 118.91% | 47.59% | 0.23 | |
 AXSM | 12.98B | 252.16 | -68.52 | 65.55% | -26.59% | -260.01% | 2.73 | |
 CORT | 8.78B | 81.75 | 99.70 | 12.79% | 6.23% | 7.5% | 0.01 | |
 PTCT | 6.51B | 78.53 | 10.09 | 114.51% | -22.58% | |||
 JAZZ | 14.24B | 226.93 | -38.86 | 4.88% | 0.66% | 0.71% | 1.26 | |
 SUPN | 2.51B | 43.58 | -64.09 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PRAX | 7.8B | 270.01 | -20.03 | -100% | -43.02% | 0.00 |
Compare BTAI vs Peers
BioXcel Therapeutics, Inc. (BTAI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BTAI Income Statement
BioXcel Therapeutics, Inc. (BTAI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 375K | 1.38M | 2.27M | 642K | 680K |
Revenue Growth % | - | - | - | - | - | - | 268% | 64.2% | -71.67% | -63.28% |
Cost of Goods Sold | 1K | 17K | 156K | 0 | 0 | 20K | 1.26M | 2.14M | 164K | 491K |
COGS % of Revenue | - | - | - | - | - | 5.33% | 91.3% | 94.57% | 25.55% | - |
Gross Profit | -1K▲ 0% | -17K▼ 1600.0% | -156K▼ 817.6% | 0▲ 100.0% | 0▲ 0% | 355K▲ 0% | 120K▼ 66.2% | 123K▲ 2.5% | 478K▲ 288.6% | 189K▲ 0% |
Gross Margin % | - | - | - | - | - | 94.67% | 8.7% | 5.43% | 74.45% | 27.79% |
Gross Profit Growth % | - | -1600% | -817.65% | 100% | - | - | -66.2% | 2.5% | 288.62% | - |
Operating Expenses | 4.54M | 19.96M | 33.6M | 82.3M | 106.94M | 160M | 171.9M | 67.37M | 50.74M | 50.48M |
OpEx % of Revenue | - | - | - | - | - | 42666.67% | 12456.67% | 2972.99% | 7904.21% | - |
Selling, General & Admin | 1.85M | 5.4M | 7.8M | 24.65M | 54.23M | 68.76M | 83.41M | 34.49M | 20.49M | 21.99M |
SG&A % of Revenue | - | - | - | - | - | 18336.27% | 6044.42% | 1522.15% | 3192.21% | - |
Research & Development | 2.69M | 14.56M | 25.8M | 58.54M | 52.71M | 91.24M | 84.33M | 30.43M | 30.25M | 28.65M |
R&D % of Revenue | - | - | - | - | - | 24330.4% | 6110.58% | 1343.12% | 4711.99% | - |
Other Operating Expenses | 0 | 0 | 0 | -888K | -1K | 0 | 4.16M | 2.44M | 0 | -163K |
Operating Income | -4.54M▲ 0% | -19.96M▼ 340.0% | -33.6M▼ 68.3% | -82.3M▼ 144.9% | -106.94M▼ 29.9% | -159.65M▼ 49.3% | -171.78M▼ 7.6% | -67.25M▲ 60.9% | -50.27M▲ 25.2% | -50.29M▲ 0% |
Operating Margin % | - | - | - | - | - | -42572% | -12447.97% | -2967.56% | -7829.75% | -7395% |
Operating Income Growth % | -114.01% | -339.98% | -68.32% | -144.92% | -29.94% | -49.29% | -7.6% | 60.85% | 25.25% | - |
EBITDA | -4.54M | -19.95M | -33.45M | -82.11M | -106.64M | -159.32M | -171.46M | -66.94M | -49.97M | -50M |
EBITDA Margin % | - | - | - | - | - | -42484.8% | -12424.93% | -2953.93% | -7783.02% | -7353.53% |
EBITDA Growth % | - | -339.7% | -67.69% | -145.5% | -29.87% | -49.4% | -7.62% | 60.96% | 25.35% | 5.43% |
D&A (Non-Cash Add-back) | 1K | 17K | 156K | 188K | 297K | 327K | 318K | 309K | 300K | 282K |
EBIT | -4.54M | -19.27M | -32.97M | -82.3M | -106.89M | -157.54M | -165.74M | -44.47M | -52.91M | -59.77M |
Net Interest Income | -2K | 0 | 633K | 128K | -36K | -5.68M | -7.67M | -12.53M | -15.92M | -16.19M |
Interest Income | 0 | 0 | 633K | 155K | 4K | 2.53M | 5.65M | 2.6M | 1.07M | 998K |
Interest Expense | 2K | 0 | 0 | 27K | 40K | 8.21M | 13.31M | 15.13M | 16.98M | 17.19M |
Other Income/Expense | -2K | 692K | 633K | 128K | 3K | -6.11M | -7.27M | 7.65M | -19.63M | -25.05M |
Pretax Income | -4.54M▲ 0% | -19.27M▼ 324.5% | -32.97M▼ 71.1% | -82.17M▼ 149.2% | -106.93M▼ 30.1% | -165.76M▼ 55.0% | -179.05M▼ 8.0% | -59.6M▲ 66.7% | -69.9M▼ 17.3% | -75.33M▲ 0% |
Pretax Margin % | - | - | - | - | - | -44201.87% | -12974.86% | -2630.14% | -10887.38% | -11078.53% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -4.54M▲ 0% | -19.27M▼ 324.5% | -32.34M▼ 67.8% | -82.17M▼ 154.1% | -106.93M▼ 30.1% | -165.76M▼ 55.0% | -179.05M▼ 8.0% | -59.6M▲ 66.7% | -69.9M▼ 17.3% | -75.33M▲ 0% |
Net Margin % | - | - | - | - | - | -44201.87% | -12974.86% | -2630.14% | -10887.38% | -11078.53% |
Net Income Growth % | -114.1% | -324.54% | -67.8% | -154.12% | -30.14% | -55.01% | -8.02% | 66.71% | -17.28% | -88.04% |
Net Income (Continuing) | -4.54M | -19.27M | -32.97M | -82.17M | -106.93M | -165.76M | -179.05M | -59.6M | -69.9M | -75.33M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4.41▲ 0% | -21.16▼ 379.8% | -32.38▼ 53.0% | -60.63▼ 87.2% | -64.87▼ 7.0% | -94.67▼ 45.9% | -98.35▼ 3.9% | -23.51▲ 76.1% | -5.73▲ 75.6% | -6.17▲ 0% |
EPS Growth % | -114.08% | -379.82% | -53.02% | -87.25% | -6.99% | -45.94% | -3.89% | 76.1% | 75.63% | 50.44% |
EPS (Basic) | -4.41 | -21.16 | -32.38 | -60.63 | -64.87 | -94.67 | -98.35 | -23.51 | -5.73 | - |
Diluted Shares Outstanding | 1.03M | 910.72K | 1.02M | 1.36M | 1.65M | 1.75M | 1.82M | 2.54M | 12.21M | 12.21M |
Basic Shares Outstanding | 1.03M | 910.72K | 1.02M | 1.36M | 1.65M | 1.75M | 1.82M | 2.54M | 12.21M | 12.21M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BTAI Balance Sheet
BioXcel Therapeutics, Inc. (BTAI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 890K | 43.17M | 34.11M | 217.06M | 236.81M | 202.87M | 72.14M | 37.39M | 44.69M | 33.91M |
Cash & Short-Term Investments | 887K | 42.56M | 32.43M | 213.12M | 232.97M | 193.72M | 65.22M | 29.85M | 28.41M | 17.18M |
Cash Only | 887K | 42.56M | 32.43M | 213.12M | 232.97M | 193.72M | 65.22M | 29.85M | 28.41M | 17.18M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 115K | 0 | 0 | 0 | 248K | 71K | 131K | 233K | 216K |
Days Sales Outstanding | - | - | - | - | - | 241.39 | 18.78 | 21.1 | 132.47 | 62.53 |
Inventory | 0 | 0 | 0 | 0 | 0 | 1.99M | 1.99M | 679K | 722K | 500K |
Days Inventory Outstanding | - | - | - | - | - | 36.23K | 576.76 | 115.65 | 1.61K | 406.44 |
Other Current Assets | 0 | 0 | 0 | 984K | 956K | 3.84M | 2.08M | 1.44M | 15.31M | 16.01M |
Total Non-Current Assets | 465K | 378K | 2.29M | 2.87M | 2.63M | 2.98M | 1.56M | 944K | 231K | 117K |
Property, Plant & Equipment | 4K | 327K | 2.23M | 2.78M | 2.54M | 2.06M | 1.47M | 857K | 231K | 117K |
Fixed Asset Turnover | - | - | - | - | - | 0.18x | 0.94x | 2.64x | 2.78x | 2.12x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 461K | 51K | 51K | 87K | 86K | 925K | 87K | 87K | 0 | 0 |
Total Assets | 1.35M▲ 0% | 43.55M▲ 3113.9% | 36.39M▼ 16.4% | 219.94M▲ 504.4% | 239.44M▲ 8.9% | 205.85M▼ 14.0% | 73.7M▼ 64.2% | 38.34M▼ 48.0% | 44.92M▲ 17.2% | 34.02M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.00x | 0.02x | 0.06x | 0.01x | 0.02x |
Asset Growth % | 19257.14% | 3113.95% | -16.43% | 504.35% | 8.87% | -14.03% | -64.2% | -47.98% | 17.16% | -63.59% |
Total Current Liabilities | 2.34M | 4.66M | 8.47M | 11.84M | 16.67M | 32.9M | 27.27M | 22.23M | 53.93M | 54.99M |
Accounts Payable | 444K | 1.6M | 4.95M | 3.98M | 4.68M | 10.23M | 13.65M | 15.99M | 14.7M | 16.25M |
Days Payables Outstanding | 162.06K | 34.44K | 11.59K | - | - | 186.66K | 3.96K | 2.72K | 32.72K | 11.88K |
Short-Term Debt | 371K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24.93M | 22.43M |
Deferred Revenue (Current) | 0 | 0 | -164K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 2.04M | 2.07M | 3.97M | 6.46M | 163K | 142K | 14.26M | 16.32M |
Current Ratio | 0.38x | 9.26x | 4.03x | 18.33x | 14.21x | 6.17x | 2.65x | 1.68x | 0.83x | 0.62x |
Quick Ratio | 0.38x | 9.26x | 4.03x | 18.33x | 14.21x | 6.11x | 2.57x | 1.65x | 0.82x | 0.61x |
Cash Conversion Cycle | - | - | - | - | - | -150.19K | -3.36K | -2.59K | -30.98K | -11.41K |
Total Non-Current Liabilities | 0 | 0 | 1.03M | 1.4M | 1.1M | 96.18M | 102.94M | 109.21M | 86.45M | 84.57M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 93.05M | 100.6M | 102.51M | 84.66M | 77.86M |
Capital Lease Obligations | 0 | 0 | 1.03M | 1.4M | 1.1M | 786K | 440K | 65K | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 2.34M | 1.91M | 6.63M | 1.79M | 6.72M |
Total Liabilities | 2.34M | 4.66M | 9.5M | 13.24M | 17.77M | 129.08M | 130.21M | 131.44M | 140.38M | 139.57M |
Total Debt | 371K | 0 | 1.03M | 1.64M | 1.4M | 94.16M | 101.38M | 102.95M | 109.59M | 100.29M |
Net Debt | -516K | -42.56M | -31.4M | -211.48M | -231.57M | -99.57M | 36.16M | 73.09M | 81.18M | 83.11M |
Debt / Equity | - | - | 0.04x | 0.01x | 0.01x | 1.23x | - | - | - | -0.95x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -2.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.66x |
Interest Coverage | -2268.50x | - | - | -3048.04x | -2672.30x | -19.18x | -12.45x | -2.94x | -3.12x | -3.48x |
Total Equity | -982K▲ 0% | 38.89M▲ 4060.2% | 26.89M▼ 30.8% | 206.7M▲ 668.5% | 221.67M▲ 7.2% | 76.78M▼ 65.4% | -56.51M▼ 173.6% | -93.1M▼ 64.8% | -95.46M▼ 2.5% | -105.54M▲ 0% |
Equity Growth % | -203.09% | 4060.18% | -30.84% | 668.53% | 7.24% | -65.36% | -173.6% | -64.76% | -2.54% | -68.33% |
Book Value per Share | -0.95 | 42.70 | 26.42 | 152.52 | 134.48 | 43.85 | -31.04 | -36.73 | -7.82 | -8.65 |
Total Shareholders' Equity | -982K | 38.89M | 26.89M | 206.7M | 221.67M | 76.78M | -56.51M | -93.1M | -95.46M | -105.54M |
Common Stock | 10K | 16K | 18K | 24K | 28K | 28K | 30K | 49K | 76K | 27K |
Retained Earnings | -4.45M | -23.72M | -56.69M | -138.86M | -245.79M | -411.55M | -590.6M | -650.2M | -720.09M | -732.78M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1K | -18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BTAI Cash Flow Statement
BioXcel Therapeutics, Inc. (BTAI) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.2M | -13.51M | -27.28M | -66.35M | -82.15M | -135.34M | -155.01M | -72.03M | -57.62M | -57.38M |
Operating CF Margin % | - | - | - | - | - | -36090.93% | -11232.32% | -3178.6% | -8974.3% | - |
Operating CF Growth % | -69.71% | -515.16% | -101.94% | -143.22% | -23.82% | -64.74% | -14.53% | 53.53% | 20.01% | 36.73% |
Net Income | -4.54M | -19.27M | -32.97M | -82.17M | -106.93M | -165.76M | -179.05M | -59.6M | -69.9M | -75.33M |
Depreciation & Amortization | 1K | 17K | 156K | 188K | 297K | 327K | 318K | 309K | 300K | 282K |
Stock-Based Compensation | 1.61M | 3.08M | 3.14M | 14.61M | 19.45M | 17.34M | 18.61M | 6.16M | 2.77M | 3.02M |
Deferred Taxes | 0 | 0 | -3.45M | -14.99M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.61M | 3.12M | 3.45M | 14.99M | 46K | 2.35M | 3.1M | -12.86M | 10.92M | 13.42M |
Working Capital Changes | 736K | 2.66M | 2.39M | 1.02M | 4.98M | 10.4M | 2.02M | -6.03M | -1.7M | 1.23M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | -248K | 177K | -60K | -102K | -216K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | -1.99M | -6K | 1.31M | -43K | 142K |
Change in Payables | 737K | 3.2M | 3.58M | 3.03M | 4.85M | 13.03M | -3.22M | -4.33M | 6.97M | 11.46M |
Cash from Investing | 0 | -340K | -870K | -316K | -445K | -139K | -20K | 0 | 0 | 0 |
Capital Expenditures | 0 | -340K | -870K | -316K | -445K | -139K | -20K | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | 37.07% | 1.45% | - | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -340K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 3.08M | 55.53M | 18.01M | 247.36M | 102.45M | 96.24M | 26.52M | 36.66M | 56.52M | 43.55M |
Debt Issued (Net) | 438K | -371K | 0 | 0 | 0 | 98.6M | 0 | -2.5M | 0 | -8.11M |
Equity Issued (Net) | 2.06M | 56.51M | 17.81M | 246.76M | 100.99M | 0 | 27.03M | 39.69M | 56.53M | 51.67M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -9.02M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 584K | -615K | 201K | 598K | 1.45M | -2.36M | -510K | -528K | -17K | -19K |
Net Change in Cash | 887K▲ 0% | 41.68M▲ 4598.8% | -10.14M▼ 124.3% | 180.69M▲ 1882.2% | 19.85M▼ 89.0% | -39.24M▼ 297.7% | -128.5M▼ 227.5% | -35.37M▲ 72.5% | -1.1M▲ 96.9% | -13.83M▲ 0% |
Free Cash Flow | -2.2M▲ 0% | -13.85M▼ 530.6% | -28.15M▼ 103.3% | -66.67M▼ 136.8% | -82.6M▼ 23.9% | -135.48M▼ 64.0% | -155.03M▼ 14.4% | -72.03M▲ 53.5% | -57.62M▲ 20.0% | -57.38M▲ 0% |
FCF Margin % | - | - | - | - | - | -36128% | -11233.77% | -3178.6% | -8974.3% | -8438.38% |
FCF Growth % | -69.18% | -530.65% | -103.26% | -136.82% | -23.9% | -64.02% | -14.43% | 53.54% | 20.01% | 13.54% |
FCF per Share | -2.13 | -15.21 | -27.65 | -49.19 | -50.11 | -77.38 | -85.15 | -28.41 | -4.72 | -4.70 |
FCF Conversion (FCF/Net Income) | 0.48x | 0.70x | 0.84x | 0.81x | 0.77x | 0.82x | 0.87x | 1.21x | 0.82x | 0.76x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 2.7M | 7.55M | 7.97M | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BTAI Key Ratios
BioXcel Therapeutics, Inc. (BTAI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -101.67% | -98.31% | -70.35% | -49.93% | -111.08% | -1766.94% | - | - | 75.79% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | 216.03% |
Gross Margin | - | - | - | - | - | 94.67% | 8.7% | 5.43% | 74.45% | 27.79% |
Net Margin | - | - | - | - | - | -44201.87% | -12974.86% | -2630.14% | -10887.38% | -11078.53% |
Debt / Equity | - | - | 0.04x | 0.01x | 0.01x | 1.23x | - | - | - | -0.95x |
Interest Coverage | -2268.50x | - | - | -3048.04x | -2672.30x | -19.18x | -12.45x | -2.94x | -3.12x | -3.48x |
FCF Conversion | 0.48x | 0.70x | 0.84x | 0.81x | 0.77x | 0.82x | 0.87x | 1.21x | 0.82x | 0.76x |
Revenue Growth | - | - | - | - | - | - | 268% | 64.2% | -71.67% | -63.28% |
Related:BTAI Dividend History·BTAI Revenue History·BTAI Price History·BTAI P/E History·BTAI Financial Ratios·BTAI Institutional Holders
BTAI SEC Filings & Documents
BioXcel Therapeutics, Inc. (BTAI) SEC filings — annual & quarterly reports (10-K, 10-Q)
BTAI Frequently Asked Questions
BioXcel Therapeutics, Inc. (BTAI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioXcel Therapeutics, Inc. (BTAI) reported $0.7M in revenue for fiscal year 2025.
BioXcel Therapeutics, Inc. (BTAI) saw revenue decline by 71.7% over the past year.
BioXcel Therapeutics, Inc. (BTAI) reported a net loss of $75.3M for fiscal year 2025.
Dividend & Returns
BioXcel Therapeutics, Inc. (BTAI) had negative free cash flow of $57.4M in fiscal year 2025, likely due to heavy capital investments.